Resolution of subretinal haemorrhage and fluid after intravitreal bevacizumab in aggressive peripapillary subretinal neovascularization.
Soliman
Wael
W
Department of Ophthalmology, Herlev Hospital, University of Copenhagen, Herlev, Denmark. waeso101@herlevhosp.kbhamt.dk
Lund-Andersen
Henrik
H
Larsen
Michael
M
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D001826:Body Fluids / Q000378:metabolism; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy; D005122:Exudates and Transudates / Q000378:metabolism; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D012166:Retinal Hemorrhage / Q000175:diagnosis / Q000188:drug therapy* / Q000378:metabolism; D015861:Retinal Neovascularization / Q000175:diagnosis / Q000188:drug therapy*; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab